Pulmonx (NASDAQ:LUNG – Get Free Report) and LivaNova (NASDAQ:LIVN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.
Analyst Ratings
This is a summary of current ratings and price targets for Pulmonx and LivaNova, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| LivaNova | 0 | 3 | 9 | 0 | 2.75 |
Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 173.81%. LivaNova has a consensus target price of $101.22, suggesting a potential upside of 9.50%. Given Pulmonx’s higher possible upside, analysts plainly believe Pulmonx is more favorable than LivaNova.
Profitability
This table compares Pulmonx and LivaNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -47.93% | -98.23% | -35.89% |
| LivaNova | 13.01% | 16.10% | 7.85% |
Insider and Institutional Ownership
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 0.3% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Pulmonx and LivaNova”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $88.78 million | 1.37 | -$54.00 million | ($1.01) | -2.77 |
| LivaNova | $1.39 billion | 3.67 | -$242.47 million | $3.00 | 30.81 |
Pulmonx has higher earnings, but lower revenue than LivaNova. Pulmonx is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Pulmonx has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Summary
LivaNova beats Pulmonx on 11 of the 14 factors compared between the two stocks.
About Pulmonx
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
About LivaNova
LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
